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Abstract
Many cancer cells display the Warburg effect, that is, enhanced glycolysis followed by fermentation (conversion
of pyruvate to lactate). Recently, the molecular basis for these effects has started to be elucidated, and the up-
regulation of the lactate dehydrogenase A (LDH-A) isoform of lactate dehydrogenase is felt to be a major molecular
mediator of this phenomenon. Moreover, LDH-A expression in tumor tissue and LDH-A levels in blood portend a
bad prognosis, and LDH-A blockade can lead to tumor growth inhibition in tumor transplant models. We have
extended existing data (some of which were published during the time when we were carrying out our studies)
in two important ways: 1) inhibition of LDH-A in a glycolytic lung cancer cell line results in reactive oxygen species–
mediated apoptosis and increased sensitivity to the chemotherapeutic drug paclitaxel and 2) inhibition of fer-
mentative glycolysis can also be accomplished by activation of the pyruvate dehydrogenase complex by the drug
dichloroacetate, now undergoing clinical trials, and that this phenomenon can be monitored in vivo in a noninva-
sive real-time manner through magnetic resonance spectroscopy using hyperpolarized pyruvate. Collectively,
these data suggest that in vivo effects of drugs that redirect the fate of pyruvate, and hence are aimed at reversing
the Warburg effect, could be monitored through the use of hyperpolarized magnetic resonance spectroscopy, a
method that is scalable to human use.
Neoplasia (2011) 13, 60–71
Introduction
Many cancer cells display enhanced glycolysis followed by fermentation
(conversion of pyruvate to lactate), known as theWarburg effect [1]. Re-
cently, the molecular basis for these effects has started to be elucidated:
part of it relates to the induction of the so-called hypoxia-inducible
factor 1 alpha (HIF-1α), which occurs as a consequence of hypoxia
and alterations in certain oncogenes or tumor suppressor genes. For
example, activation of the myc and ras oncogenes or loss of tumor sup-
pressor genes such as VHL (von Hippel Lindau) and FH (fumarate
hydratase) elevates HIF-1α levels. Increased HIF expression results in
the increased transcription of genes involved in glucose transport,
glucose metabolism, lactate formation (through activation of lactate
dehydrogenase-A [LDH-A]—see below) [2,3] and lactate export from
cells [4]. HIF is also thought to block the entry of pyruvate into the
Krebs cycle by inhibiting the pyruvate dehydrogenase (PDH) complex
[5]. In addition, recent discoveries on the p53 tumor suppressor also
suggest that this protein can regulate glucose metabolism. p53 muta-
tions result in diminished oxidative phosphorylation [6]. Collectively,
these studies provide an explanation for the Warburg effect.
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The lactate dehydrogenases are involved in the interconversion of
pyruvate and lactate. There are two LDH subunits encoded by two
separate genes, LDH-A and LDH-B. These two subunits associate to
form five different isoforms of tetrameric LDH: LDH1 (LDH-B4),
LDH2 (LDH-B3A1), LDH3 (LDH-B2A2), LDH4 (LDH-B1A3),
and LDH5 (LDH-A4). LDH1 is effective in the conversion of lac-
tate into pyruvate, whereas LDH5 is effective in the conversion of
pyruvate into lactate. The observation that HIF-1α increases fermen-
tation is likely mediated by the induction of LDH-A [7–9]. LDH-A
is upregulated not only by HIF and c-Myc at a transcriptional level
but also by protein kinase A and protein kinase C at the messenger
RNA stability level [10,11].
The notion that LDH-A may regulate tumor growth is suggested
by studies that LDH-A overexpression in non–small cell lung cancer
(NSCLC) is linked to tumor hypoxia, angiogenic factor production,
and poor prognosis [8], and similar data have been shown in colorectal
cancer [7]. Increased LDH-A expression also results in increased extra-
cellular acidity because the extrusion of lactate is accompanied by proton
transport through one of several monocarboxylate transporters (MCTs)
[12,13]. It has now been documented that reduction of fermentative
glycolysis through LDH-A blockade results in reduced tumor growth,
implicating LDH-A as another viable therapeutic target for tumorigen-
esis [14,15]. Therefore, we asked whether inhibition of LDH-A in the
highly glycolytic NSCLC cell line A549 results in reduced tumor
growth. Moreover, we asked whether we could visualize the decrease
in pyruvate to lactate flux in a noninvasive real-time manner. Because
we did not have access to LDH-A inhibitors, we asked whether the in-
hibition of fermentative glycolysis as measured by decreased pyruvate to
lactate flux can be achieved by activation of PDH by dichloroacetate
(DCA) that will shuttle pyruvate toward tricarboxylic acid cycle
(TCA) and away from LDH-A catalyzed reaction.
DCA is a small molecule of 150 Da. In vitro, DCA activates PDH
by inhibiting PDH kinase (PDK) at concentrations of 10 to 250 μM
depending on the isoform [16]. The isozyme PDKII is expressed con-
stitutively in most tissues and is the most sensitive to DCA [17]. The
enhanced PDH activity diverts metabolism from fermentative glycolysis
to glucose oxidation and decreases mitochondrial membrane potential
polarization, resulting in the opening of mitochondrial transition pores.
This allows for the translocation of reactive oxygen species and cyto-
chrome c from the mitochondria to the cytoplasm, inducing apoptosis
through the activation of caspases. DCA has undergone extensive clin-
ical trials for lactic acidosis, sepsis, burns, and cirrhosis with doses rang-
ing from 25 to 100mg/kg per day orally or intravenously [18,19]. So far,
no major adverse effects of DCA treatment at these doses have been re-
ported, except peripheral neuropathy, which was reversible on drug
discontinuation (reviewed in Root et al. [35]). Recent work also shows
that facilitation of pyruvate oxidation byDCA treatment leads to tumor
growth reduction in many solid tumors in vitro and in vivo, including
NSCLC, glioblastoma, and prostate cancer [20,21]. DCA is in clinical
trials for glioblastoma, NSCLC, and breast cancer (clinicaltrials.gov).
To assess the response of tumors to administration of DCA, we made
use of hyperpolarized nuclear magnetic resonance (NMR) spectroscopy
to noninvasively monitor the conversion of pyruvate into lactate. Until
recently, studies of in vivometabolism using NMR have been hampered
by the low intrinsic sensitivity of the method. The advent of practical
techniques for preparing liquid solutions of hyperpolarized 13C-labeled
metabolites [22,23] has yielded dramatic increases in sensitivity, making
it possible to perform real-time imaging and spectroscopy of metabo-
lism. [1-13C]pyruvate is readily hyperpolarized using dynamic nuclear
polarization, and rapid conversion of pyruvate into lactate is observed
in vivo [24]. Although it has been argued that the lactate signal is at
least partially due to exchange of the 13C label between hyperpolarized
pyruvate and the endogenous lactate pool, rather than net synthesis of
lactate [25,26], this method provides a measure of both the size of the
endogenous lactate pool and the activity of LDH. In addition, transport
of pyruvate by MCT1 has been shown to play an important role in
lactate formation in cell culture [27]. Studies making use of hyper-
polarized pyruvate in TRAMP mice (a murine model of prostate can-
cer) have shown that lactate signal increases with cancer progression and
correlates with tumor histologic grade [28]. Moreover, data from a
murine EL-4 lymphoma model show that the lactate signal is reduced
after chemotherapeutic intervention [25]. Other recent studies have
shown that inhibition of phosphatidylinositol 3-kinase also leads to re-
duced lactate signal [29]. Pyruvate is only one of several substrates that
can be studied using these techniques; other metabolites including
fumarate [30], acetate [31], succinate [32] choline [33], and fructose
[34] have also been described.
As emphasized above, the lactate signal obtained after administra-
tion of hyperpolarized pyruvate is determined by several factors. Chief
among these is the so-called “exchange” signal, which results from ex-
change of the 13C label between the injected pyruvate and the endoge-
nous lactate pool. This signal can be sizeable even when there is little
or no net conversion of pyruvate into lactate and depends on both the
activity of LDH and the size of the endogenous lactate pool. Indeed,
previous studies in cell culture have shown that addition of exogenous,
unlabeled lactate results in an increase in lactate signal after adminis-
tration of hyperpolarized pyruvate [25]. Consequently, interventions
that reduce levels of endogenous lactate will result in reduced lactate sig-
nal even if the activity of LDH is unchanged. By contrast, the flux of
pyruvate through PDH, which produces acetyl-CoA and labeled bi-
carbonate, does not possess a similar exchange component. The bi-
carbonate signal is a direct measure of net flux through PDH, which
is typically much smaller than the exchange process that accounts for
much of the lactate signal. Indeed, it was not until the work of Kohler
et al. [24] that bicarbonate was routinely detected with spectroscopic
imaging, and even then the signal was quite small in comparison to
the lactate signal. These observations have special relevance to studies
of metabolism in the Warburg effect, where interventions that shift
pyruvate metabolism away from lactate and toward acetyl-CoA are
sought. In particular, when such interventions reduce the size of the
endogenous lactate pool, they will result in reduced lactate exchange
signal. However, this reduction in lactate signal need not be accom-
panied by a proportionate increase in bicarbonate signal; indeed, there




Cell culture medium was purchased from American Type Culture
Collection (ATCC, Manassas, VA). 2-Deoxy-D-glucose and lentiviral
constructs were purchased from SigmaAldrich (St Louis,MO), and viral
power kit and packaging cell line 293FT were purchased from In-
vitrogen (Carlsbad, CA). Sheep polyclonal LDH-A antibodies were pur-
chased from Abcam (Cambridge, MA). Rabbit polyclonals for activated
caspase-3 and activated poly (ADP-ribose) polymerase (PARP) were
purchased from Cell Signaling (Cambridge, MA). The assay kit for
measuring ATP was purchased from Roche (Indianapolis, IN). The
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lactate measurement kit was purchased from CMA microdialysis
(N. Chelmsford, MA). Cell cycle reagents and annexin Vassay kits were
purchased from Guava Technologies (Hayward, CA). Athymic mice for
tumor implantation were purchased from Charles River Laboratories
(Wilmington, MA). A549 cells were maintained in Ham’s F12 medium
with glutamine and sodium pyruvate with 10% fetal calf serum (Sigma-
Aldrich). The hypoxic conditions (0.1%-0.5% O2) were maintained in
a controlled atmosphere chamber (Billups-Rothenberg, DelMar, CA) at
37°C in certified 5% CO2/94.5% nitrogen.
Generation of LDH-A–Deficient Cell Lines
A549 cells were infected with empty small hairpin RNA (shRNA)
vector control and three different LDH-A shRNA lentiviruses as de-
scribed [35]. Briefly, recombinant lentivirus particles were produced
by transient transfection of 293T cells. Subconfluent 293FT cells were
cotransfected with 3 μg of an shRNA plasmid, and 9 μg of viral power
packaging mix (an optimized proprietary mix of three plasmids, pLP1,
pLP2, and pLP/VSVG from Invitrogen) using Lipofectamine 2000
(Invitrogen). After 16 hours, the culturemediumwas switched to a regu-
lar growth medium, and cells were allowed to incubate for an additional
48 hours. Conditioned cell culture medium containing recombinant
lentiviral particles was harvested and frozen. A549 cells were treated
with the above cell culture supernatant containing lentiviral particles
for 24 hours. These cells were then selected in puromycin (Sigma-
Aldrich) to generate stable cell lines encoding empty vector shRNA
and LDH-A shRNA. The selected cell lines were validated for dimin-
ished LDH-A expression byWestern blot analysis. Briefly, total cellular
proteins were separated by SDS-PAGE and electrotransferred to poly-
vinylidene fluoride membranes and immunoblotted with anti-LDH
antibody overnight at 4°C. After washing with TBS-T, the membrane
was incubated with secondary antibody for 30 minutes. Protein bands
were detected using SuperSignal West Pico Chemiluminescent sub-
strate from Pierce (Rockford, IL). To demonstrate that shRNA is spe-
cific for LDH-A versus B isoform, we obtained HCCT 116 cells that
are deficient in methytransferases and express LDH-B [36,37] (LDH-B
is hypermethylated and hence not expressed in most cancer cells [38]).
These HCCT 116 cells deficient in methytransferases, known as DKO
cells [36], were used for shRNA-mediated LDH-A knockdown as de-
scribed above.
Proliferation Assay
Control and LDH-A–deficient cell lines were plated in 60-mm dish
at a density of 1 × 105 cells/dish in HAM’s F12 medium supplemented
with 10% FBS for 24 hours at 37°C in a 5% CO2 incubator. After 24,
48, 72, 96, and 120 hours of initial plating, cells were scraped, washed
with PBS and resuspended in 1 ml of Hanks’ buffer, and counted. All
samples were assayed in duplicate to generate proliferation curves as
described [5]. For proliferation assays done in hypoxia, the hypoxic
conditions (0.1%-0.5% O2) were maintained in a controlled atmo-
sphere chamber (Billups-Rothenberg) at 37°C in certified 5% CO2/
94.5% nitrogen.
Lactate Accumulation
To assess whether LDH-A–deficient cell lines have a diminished ac-
cumulation of lactate, we measured lactate accumulation in control and
LDH-A–deficient cell lines as described [39]. Briefly, the cell culture–
conditioned supernatant was used to measure lactate levels by a simple
calorimetric analysis based on the reduction of the tetrazolium salt INT
in a nicotinamide adenine dinucleotide (NADH)-coupled enzymatic
reaction to formazan, which is water-soluble and exhibits an absorption
maximum at 492 nm. The intensity of the red color formed is propor-
tional to the lactate concentration in the conditioned medium.
Cell Cycle Analysis
Cells were fixed in 70%ethanol, stainedwith cell cycle reagent (Guava
Technologies, Hayward, CA), and subjected to fluorescence-activated
cell sorting on an EasyCite Plus flowcytometer (Guava Technologies).
Intracellular ATP
Intracellular ATP levels in control and LDH-A–deficient cells were
measured according to the manufacturer’s instructions. In brief, cell
lysates were collected, and luminescence was measured using a lumines-
cence reader (Molecular Devices, Sunnyvale, CA) and normalized to
protein concentration.
Annexin V Assay
Apoptosis was measured by Guava PCA-96 Nexin (Guava Technol-
ogies) as per the manufacturer’s protocol. Briefly, cells were harvested
and resuspended in 1× Nexin buffer with annexin V–PE, and Nexin
7-AAD. The cells were allowed to incubate for 15minutes and analyzed
in the Guava flow cytometer.
LDH Enzyme Activity
LDH-A activity was measured in the direction of reduction of pyru-
vate to lactate by monitoring the changes in the absorbance of NADH
at 340 nm, 25°C in potassium phosphate buffer, pH 7.4. Briefly,
the reaction mixture contained 50 mM potassium phosphate buffer
(pH 7.4) and pyruvate (200 μM). The reaction was initiated by the
addition of cell extract prepared in potassium phosphate buffer and
NADH (250 μM), and decrease in absorbance at 340 nm was moni-
tored every 4 minutes.
Oxygen Consumption and Proton Production Rate Analysis
TheXF24Extracellular Flux analyzer (Seahorse Biosciences, Billerica,
MA) is a fully integrated 24-well instrument that measures in real-time
the uptake and release of metabolic end products. Each XF24 assay
well contains a disposable sensor cartridge, embedded with 24 pairs of
fluorescent biosensors (oxygen and pH), coupled to fiber-optic wave-
guides. The waveguides deliver light rays at various excitation wave-
lengths (oxygen = 532 nm, pH = 470 nm) and transmit a fluorescent
signal (oxygen = 650 nm, pH=530 nm) to a set of highly sensitive photo-
detectors. This technology was used to measure oxygen consumption
(OCR) and proton production rate (PPR), both expressed in picomoles
per minute in control and LDH-A–deficient cell lines as described [40].
Soft Agar Growth Assay
Sixty-millimeter plates were layered with 1.4% agarose in phenol
red–free 2× DMEM and allowed to solidify. A549 cells expressing con-
trol shRNA and LDH-A shRNA were mixed in 0.8% agarose in 2×
DMEM and seeded onto these 1.4% agarose layers (30,000 cells per
plate). These plates were allowed to solidify for 15 minutes and were
covered with growth medium. The growth medium was changed every
3 days for 4 weeks. Cells were washed with PBS and fixed in 100%
methanol for 30 minutes followed by staining with 0.5% crystal violet
for 1 hour. The plates were washed with PBS, and colonies with size
greater than 0.5 mm were counted under the microscope. The experi-
ment was performed in triplicates, and four random fields per dish were
counted. Results represent two independent experiments.
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Reactive Oxygen Species Measurements
Intracellular reactive oxygen species (ROS) production was measured
by stainingwith dichlorodihydrofluorescein diacetate (CM-H2DCFDA;
Invitrogen). CM-H2DCFDA is a cell-permeant indicator for reactive
oxygen species that is nonfluorescent until removal of the acetate groups
by intracellular esterases and oxidation occurs within the cell. The pro-
cedure for measuring ROS was carried out as described earlier [5], with
minor modification. Briefly, cells were loaded with 5 μM H2DCFDA
for 1 hour, washed in PBS, and incubated in fresh medium for 30 min-
utes. The cells were then subjected to FACS analysis.
Tumor Implantation
A total of 5 × 106 control and LDH-A–deficient cells (LDH-A
shRNA no. 1) were subcutaneously implanted in eight athymic mice.
The implantation was done such that each mouse had control cells on
the right flank and LDH-A–deficient cells on the left flank. Similarly, 5 ×
106 control and LDH-A–deficient cells (LDH-A shRNA no. 2) were
subcutaneously implanted in the flanks of eight athymic mice. Tumors
were measured every 7 days, and tumor volume was calculated as de-
scribed before [41]. Tumor lysates were prepared by homogenization
of tumor tissues in lysis buffer and were separated by SDS-PAGE and
electrotransferred to PDVF membranes and immune blotted with anti-
LDH antibody as described above. For DCA administration experi-
ments, 5 × 106 A549 wild type cells were implanted in athymic mice
that were then administered DCA as described below.
TUNEL Assay
Tumor tissue from control and LDH-A–deficient tumors were
embedded in paraffin and assayed for apoptosis through terminal deoxy-
nucleotidyl transferase dUTP nick end labelling (TUNEL) staining as
described earlier [42].
Administration of DCA
The amount of 25 mg/kg DCA was administered 24 hours be-
fore the pyruvate imaging through interperitoneal injection. Another
dose of 25 mg/kg was given just before imaging intravenously by tail
vein injection.
Magnetic Resonance Imaging and Spectroscopy
Modifications of tumor metabolism in A549 xenograft tumors re-
sulting from administration of DCA were assessed using 13C NMR
spectroscopy after administration of hyperpolarized 13C1-pyruvate.
Preparation of Hyperpolarized Pyruvate
Hyperpolarized pyruvate was prepared as described previously [24].
Pyruvic acid was combined with 15 mM trityl radical (OX063; GE
Healthcare, London, UK), and 27.7 ± 0.4 mg of this mixture was then
placed in an open sample cup. The cup was placed inside a commercial
hyperpolarizer (Oxford Hypersense; Oxford Instruments, Oxfordshire,
UK) where it was frozen at 1.4 K and subjected to microwave radiation
at 50 to 100mWand a frequency of approximately 94.110 GHz. Solid-
state 13C NMR was used to monitor the growth of the carbon polariza-
tion. Themicrowave power was set to 100mWprovided that the system
could maintain a temperature of 1.4 K at this power level. Otherwise,
the power was reduced to 50 mW. If the system was unable to maintain
1.4 K at 50 mW, it was “baked out” to remove impurities from the vari-
able temperature insert and restore its ability to maintain a temperature
of 1.4 K. The choice of microwave power was found to have a negligible
impact on the solid-state polarization buildup. All samples were polar-
ized for a minimum of 40 minutes, by which time the solid-state polar-
ization had reached at least 95% of its maximum, saturated value. The
pyruvic acid was then thawed and ejected from the system using 4 ml
of hot USP saline solution (0.45% NaCl) containing 40 mM Tris and
25 mg/100 ml disodium EDTA. The sample was collected in a glass
container and mixed with a sufficient quantity of 1N sodium hydroxide
solution to obtain a pH of 7.5 ± 0.5. The resulting solution contained
approximately 78 mM hyperpolarized pyruvate.
Animal Preparation
Each mouse was anesthetized using inhaled isoflurane (2%-3%) in
a drop box and then transferred to a work area where anesthesia was
maintained by isoflurane delivered through a nose cone. A catheter
connected to a narrow extension tube was placed in the tail vein, and
a small 13C surface coil was placed over the xenograft tumor (see below).
The mouse was then placed inside a 4.7-T horizontal bore scanner
(Bruker Biospec, Billerica, MA). Proper levels of anesthesia were main-
tained using respiratory monitoring (small animal monitoring system;
SAII, Stony Brook NY) throughout the imaging study.
Magnetic Resonance Imaging and 13C Spectroscopy
Conventional proton magnetic resonance imaging (MRI) was used
to assess the size and location of the xenograft tumors and to verify
the location of the 13C surface coil. Axial T2-weighted images were ac-
quired using a RARE sequence (TR/TE = 1000/23 milliseconds) with
echo train length 4, 128 × 128matrix, 4 × 4 cm2 field of view, and 1-mm
slice thickness.
13C spectroscopicmeasurements of pyruvatemetabolism in the xeno-
graft tumors were performed using surface coil localized spectroscopy.
Depending on the size of the tumor, one of two circular surface coils was
used: a 10-mm-diameter coil was used for larger tumors, and a 6-mm-
diameter coil was used for smaller tumors. Signals acquired from the sur-
face coils were dominated by metabolites within the tumor owing to the
placement of the coils and their small diameters. The coils were oper-
ated in a transmit/receive mode. A crude estimate based on a Biot-
Savart calculation shows that in this configuration, on the axis of the
coil, just more than 90% of the NMR signal is derived from the tissue
within a depth of one coil radius from the surface of the body, cor-
responding to 3 to 5 mm for the 6- and 10-mm-diameter coils, respec-
tively. Although imperfect coil placement may result in stray signals
from tissue in the vicinity of the tumor, this technique is expected to
yield signals that are dominated by tissue within the tumor. The loca-
tion of the coil with respect to the tumor was validated by means of an
MRI-visible marker consisting of roughly 1 cm of rubber tubing, 1/8 in.
outside diameter, which was filled with water, sealed, and affixed to the
coil along its center axis. This tubing was readily visible in the axial T2-
weighted proton images described above, which were used to verify that
the coil was centered within 1 to 2 mm of the center of the tumor.
Before the imaging studies, the 13C radiofrequency transmit power
was adjusted by placing the surface coil on a phantom containing 3 M
13C-labeled sodium acetate in water. 13C spectra were acquired from
the phantom at a range of transmit power values, and the relative signal
strength for each value was measured. For in vivo studies, the transmit
power was set to a relatively low value that yielded approximately 1/10th
to 1/20th of the peak signal. This low transmit power corresponds to a
low average flip angle over the sensitivity region of the coil. With these
settings, the hyperpolarized magnetization was minimally disturbed
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by the application of radiofrequency pulses, and it was possible to
acquire dozens of spectra during a period of minutes after administra-
tion of hyperpolarized pyruvate.
After imaging the tumor and verifying the placement of the 13C
surface coil, 300 μl of hyperpolarized pyruvate solution, described
above, was administered through the tail vein catheter. Just before the
injection, an automated script was initiated on the MRI scanner that
acquired a 13C spectrum from the surface coil every 5 seconds with spec-
tral width 200.11 ppm, 8192 points, and total acquisition time of
812.65 milliseconds.
Data Analysis
The 13C spectra were apodized with a 15-Hz line-broadening filter,
phased, and baseline-corrected using software provided with the MRI
scanner (Bruker TopSpin). The spectral lines corresponding to pyruvate,
lactate, and alanine were then integrated and plotted as a function of
time. All of the signals were scaled by a common factor to obtain a peak
pyruvate signal equal to 1. The maximum lactate signal (after scaling)
was used as a measure of the relative lactate formation in each tumor.
(Owing to the scaling procedure, the lactate signal can also be thought
of as the maximum lactate signal divided by the maximum pyruvate
signal.) The lactate signals for untreated tumors and DCA-treated
tumors were then compared using a two-tailed t test.
Results
Generation and Validation of LDH-A–Deficient Cell Lines
To investigate the effects of diminished LDH-A expression, we
chose to work with A549 cells, a highly glycolytic NSCLC cell line.
A549 cells are highly glycolytic as shown by their susceptibility to 2-
deoxy-D-glucose, a well-characterized glucose analogue, which can be
phosphorylated in the first step of glycolysis but cannot undergo addi-
tional glycolytic reactions. We saw a concentration-dependent fall in
cellular ATP levels with addition of increasing amounts of 2-deoxy-
D-glucose to the culture medium (Figure 1A). We generated LDH-A–
deficient A549 stable cells using RNA interference technology. Western
blot analysis with anti–LDH-A antibody (Figure 1B) demonstrated
that cell line nos. 1 and 2, representing shRNAs targeting two different
regions within the LDH-A messenger RNA, have diminished LDH-A
protein expression compared with the cell line expressing control
shRNA. We chose to pursue further analysis with shRNA no. 1 and
shRNA no. 2. ShRNA-mediated knockdown of LDH-A in DKO cells
does not affect LDH-B expression and confirmed specificity of LDH-
A versus LDH-B inhibition (Figure 1C ). The LDH-A–deficient cells
compared with control cells had low enzyme activity (Figure 1D), re-
sulting in low lactate levels (Figure 1E ). Oxamate, a nonspecific LDH
inhibitor, served as a positive control in these experiments. PPR analysis
Figure 1. (A) Relative ATP levels in A549 cells in the presence of increasing concentrations of 2-deoxy-D-glucose. (B)Western blot analysis of
A549 LDH-A–deficient cell lines using LDH-A antibody. (C) Western blot analysis with LDH-A and LDH-B specific antibody on control versus
LDH-A–deficient DKO cells. (D) LDH activity measurements in control and A549 LDH-A–deficient cell lines. (E) Lactate levels in control and
A549 LDH-A–deficient cell lines. (F) PPR in control and A549 LDH-A–deficient cell lines as measured by the XF24 analyzer.
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of the control cell line and LDH-A–deficient cells with the XF24
analyzer also showed that LDH-A–deficient lines produced less extra-
cellular acidification as measured through lactate accumulation assay
(Figure 1F ).
In Vitro Characterization of LDH-A–Deficient Cell Lines
To test whether cell lines deficient in LDH-A expression would show
altered cell proliferation, we characterized these stable cell lines in various
in vitro assays. As shown in Figure 2A, the LDH-A–deficient cell lines
display a proliferation defect of varying degree. To access the growth
potential in three dimensions, we used a soft agar growth assay. LDH-
A–deficient cells generated smaller colonies compared with the control
shRNA cell line, suggesting a lower tumorigenic potential (Figure 2B).
LDH-A–deficient cells also demonstrated significantly higher per-
centage of cells in G0/1 state (Figure 2B) as well as increased apoptosis
compared with the cells infected with control shRNA (Figure 2C). Via-
ble cells do not bind annexin V–PE or 7-aminoactinomycin D (7AAD)
as reflected in the lower left-hand quadrant of the dot plot. Apoptotic
cells with exposed PS but intact cell membranes bind annexin V–PE but
exclude 7AAD. Fluorescence from this population is reported in the
lower and upper right-hand quadrant. Induction of apoptosis is also
demonstrated by Western analysis of cleaved caspase-3 (Figure 2, D
and E) and cleaved PARP in LDH-A–deficient cell lines (Figure 2F ).
Because hypoxic regions in tumors must rely on glycolysis, especially
fermentative glycolysis regulated by LDH-A, an HIF-1α target, we
asked whether cells with diminished LDH-A expression versus control
Figure 2. (A) Proliferation assay analysis of A549 LDH-A–deficient cell under normoxia. (B) Soft agar colony assay for A549 LDH-A–
deficient cell lines versus control cell line. (C) Cell cycle analysis (percent cells in G0/1 in control and LDH-A–deficient cell lines. (D
and E) Apoptosis as measured by annexin V and its representation in bar format. (F) Western blot analysis in control and A549 LDH-
A–deficient cell lines for activated caspase-3 and activated PARP.
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cells would behave differently in hypoxic conditions. The proliferation
rate in a hypoxic environment is significantly slower in control as well
as LDH-A–deficient cells, with LDH-A–deficient cells showing com-
paratively more reduced growth (Figure 3A).
To determine the impact on ATP levels of LDH-A inhibition, ATP
levels were measured under normoxic and hypoxic conditions. In com-
parison to the control cell line, LDH-A–deficient cells do not show sig-
nificant ATP depletion (∼10% reduction) in normoxic condition,
suggesting that a functional OXPHOS is able to compensate for de-
creased fermentative activity. On other hand, in hypoxic conditions,
the ATP levels were significantly decreased (∼40%) in LDH-A–deficient
cells (Figure 3B). This is in agreement with the substantially reduced
proliferation rate observed in hypoxic conditions.
We were unable to see a significant increase in NADH/NAD+ ratio
in our LDH-A–deficient cell lines (data not shown). These results are
in line with our observation of an increased rate of oxygen consump-
tion in LDH-A–deficient cells and suggest enhanced activation of
OXPHOS as a result of LDH-A knockdown (Figure 3C).
In Vivo Characterization of LDH-A–Deficient Cell Lines
On the basis of our in vitro results, we hypothesized that LDH-A–
deficient cell lines might have significantly diminished growth in vivo.
We found that both of our two independent LDH-A knockdown cell
lines showed marked growth retardation in nude mice (Figure 4, A
and B: each mouse injected with both control shRNA and LDH-A
knockdown cells in the flank). Also shown is the Western blot analysis
of tumor tissue isolated from these tumors to demonstrate LDH-A
knockdown in tumor tissue. As in our in vitro data, the tumor tissue
arising from LDH-A–deficient cells showed increased apoptosis as
measured by TUNEL staining (Figure 4C ) and an assessment of the
average number of apoptotic cells in four random areas TUNEL stain-
ing (Figure 4D).
Increased ROS Generation in LDH–Deficient Cells
Mediates Apoptosis
On the basis of the observed increase in oxygen consumption in
LDH-A–deficient cells, we asked whether enhanced OXPHOS would
lead to increased formation of reactive oxygen species perhaps as a con-
sequence of increased electron flow. We found increased ROS levels
in the LDH-A–deficient cells compared with control (Figure 5A). Fur-
thermore, this ROS generation could be blocked by the antioxidant
N -acetyl cysteine (NAC), and this not only neutralized the ROS gen-
eration but also led to significant rescue from apoptosis as measured
by cleaved PARP (Figure 5B). These data suggest that increased ROS
formation occurs in LDH-A–deficient cells, and this increase is respon-
sible for the observed increase in cell death.
LDH-A Inhibition Sensitizes A549 Cells to Low Dose Paclitaxel
Increased extracellular acidity resulting from increased fermentative
glycolysis has been suggested to be responsible for more aggressive me-
tastatic behavior [9,43,44], resistance to immune recognition [45–47],
and resistance to chemotherapy [48,49]. In fact, a recent report showed
that NSCLC patients with enhanced LDH-A expression were resistant
to chemotherapy treatment [8]. Therefore, we also asked whether inhi-
bition of fermentative glycolysis can increase the efficacy of a chemo-
therapeutic drug such as paclitaxel, a chemotherapeutic drug used in
the therapy for NSCLC. Apoptosis even at low paclitaxel concentra-
tions was enhanced (Figure 6A; graphical representation in Figure 6B).
LDH-A Inhibition Is Functionally Similar to PDH Activation
Because PDH is negatively regulated by PDK enzymes (schematic
no. 1), we asked whether knockdown of PDK II resulting in PDH ac-
tivation might give us results similar to those noted with LDH-A inhi-
bition. We found that the level of OCR and ROS was significantly
higher in A549 cells with reduced PDK II expression compared with
Figure 3. (A) Proliferation assay analysis of A549 LDH-A–deficient cell lines in hypoxic conditions. (B) Intracellular ATP levels under nor-
moxic and hypoxic condition in control and LDH-A–deficient cells. (C) Oxygen consumption rate in control and LDH-A–deficient cell lines
as measured by XF24 analyzer under normoxia.
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Figure 4. (A and B) Tumor growth measurements for control and A549 LDH-A–deficient cell lines in athymic mice with corresponding
Western blot analysis of tumor tissue. C indicates control shRNA tumor tissue; L, LDH-A–deficient tumor tissue; M, mouse number. (C)
TUNEL assay to assess apoptosis, with arrows indicating apoptotic cells. (D) Average number of apoptotic cells in four random field (20×) in
control and LDH-A–deficient tumors by TUNEL staining. Note that in panels C and D, a refers to data with control shRNA, b refers to LDH-A
shRNA no. 1, and c to LDH-A shRNA no. 2.
Figure 5. (A) ROS measurements by H2DCFDA in control and LDH-A–deficient cell lines in the presence and absence of NAC. (B) Western
blot analysis of cleaved PARP in control and LDH-A–deficient cells in the presence and absence of 5 mM NAC for 55 hours.
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A549 cells expressing control shRNA, in congruence with our shRNA–
LDH-A findings (Figure 7).
Hyperpolarized Pyruvate Can Be Used to Monitor Changes
in Metabolism In Vivo
Figure 8Adisplays a typical T2-weighted axial proton image in a tumor-
bearing mouse. The bright line on the upper right indicates the center
of the 13C surface coil, which is situated over the tumor, indicated by
the green outline. Figure 8B displays the pyruvate and lactate signals
as a function of time in a pair of control (left) and DCA treated (right)
mice. A reduction in lactate signal is evident in the DCA-treated tumor.
Figure 8C displays a comparison of the lactate signals in eight stud-
ies performed using control tumors and in nine studies performed
using tumors after DCA treatment. The values of peak lactate divided
by peak pyruvate are 0.20 ± 0.07 for the control studies and 0.13 ± 0.07
for the studies with DCA treatment. A two-tailed t test yields a P value
of 0.048 for the reduction in tumor lactate signal after DCA treatment.
Discussion
The findings in this report are as follows: 1) Inhibition of LDH-A in a
glycolytic NSCLC tumor cell line results in ROS-mediated apoptosis
and increased sensitivity to the chemotherapeutic drug paclitaxel. 2)
The inhibition of fermentative glycolysis either through inhibition of
Figure 6. (A) Apoptosis measurement in control and LDH-A–deficient cells by annexin V–PE analysis in the presence or absence of 0.5 nM
paclitaxel. (B) graphical representation of A.
Figure 7. (A) OCR of control and A549 PDK2–deficient cell lines. (B) Real-time polymerase chain reaction analysis of control and A549
PDK2–deficient cell lines. (C) OCR of control and A549 LDH-A–deficient cell lines. (D) Comparative analysis of OCR between control and
A549 LDH-A–deficient cell lines and 10 mM DCA-treated A549 cells.
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LDH-A or by activation of PDH by the drug DCA can be monitored
in a noninvasive real-time manner through hyperpolarized pyruvate.
Although the molecular mechanisms leading to the increased rate of
glycolysis are not fully understood, it is hypothesized that enhanced con-
version of pyruvate to lactate in NSCLC cells is the result of increased
expression of LDH-A, a target of themyc oncogene [50,51] that is over-
expressed in NSCLC. The expression of LDH-A is abundant in tumor
cells lines compared with normal primary lung epithelial cells [7,8].
Moreover, LDH-A expression is also regulated by HIF-1α [52–54] that
further increases expression of LDH-A and decreases expression of
PDH, which regulates pyruvate entry into TCA cycle by converting
pyruvate to acetyl Co-A. The opposing effects of these two enzymes that
are regulated by HIF-1 [5,55] control the glycolytic state in solid tumor
environment. In the present study, we wanted to ask whether inhibi-
tion of LDH-A in the highly glycolytic NSCLC cell line A549, results
in reduced tumor growth and whether it can increase the efficacy of a
chemotherapeutic drug. We also asked whether we could visualize this
inhibition of decreased pyruvate to lactate flux. Moreover, because of
the lack of specific LDH-A inhibitors, we asked whether the inhibition
of fermentative glycolysis as measured by decreased pyruvate to lactate
flux can be achieved by activation of PDH by DCA that will shuttle
pyruvate toward TCA and away from LDH-A–catalyzed reaction.
To achieve these goals, we started by using RNA interference to gen-
erate stable cell lines with diminished LDH-A expression. In compari-
son to control cell lines, the LDH-A–deficient cell lines were still capable
of proliferation under normoxic condition but at a slower rate. There
was no significant difference in ATP generation in LDH-A–deficient
cells compared with control cells, suggesting either that OXPHOS is
functional to generate required ATP in the normoxic condition or that
another LDH isoform is enough to compensate for LDH-A deficiency.
However, this pattern of growth was severely restricted under hypoxic
conditions with appreciable ATP depletion in LDH-A–deficient cells
compared with control. It was rather surprising that the rate of prolifer-
ation for the control cell line was also retarded. We had expected that
control cells would use fermentative glycolysis and show similar growth
rate as observed in normoxic condition. It is possible that pH changes in
Figure 8. (A) Axial T2-weighted MR image of a typical tumor, outlined in green. The center axis of the
13C surface coil is indicated by the
bright marker at the upper left; the coil itself is situated in direct contact with the tumor. (B) Pyruvate and lactate signals acquired after
administration of hyperpolarized pyruvate in representative control (left) and DCA-treated (right) tumors as a function of time. The reduction
in lactate signal after DCA treatment is evident. (C) Distribution of peak lactate signal divided by peak pyruvate signal in control (left) and DCA-
treated (right) tumors. The black vertical lines show themaximum andminimum values, and the blue boxes indicate the range of the second
and third quartiles (i.e., the range from the 25th percentile to the 75th percentile).
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cell culture medium as a result of excess lactate production during con-
tinued hypoxia may lead to reduced cell viability. This is a key observa-
tion: LDH-A inhibition will work better under hypoxic conditions
because the cells are locked into fermentative glycolysis. Therefore, we
are tempted to hypothesize that cancer stem cells that tend to segregate
in the hypoxic niche [56,57] and are often not affected by chemotherapy
regimen, designed to inhibit rapidly proliferating cells, may be sensitive
to LDH-A inhibitor therapy.
Because ATP depletion was not a likely cause of the apoptosis in the
normoxic condition, and we observed increased oxygen consumption in
LDH-A–deficient cells, we asked whether increased oxygen consump-
tion leads to increased oxidative stress. We demonstrated that inhibition
of LDH-A results in increased ROS generation. Moreover, the neutral-
ization of ROS by NAC resulted in a significant reduction in cleaved
PARP, suggesting that ROS may play an active role in the induction
of apoptosis. The increased ROS generation by LDH-A inhibition
may result from increase in electron flux in the electron transport chain
and concomitant inability to efficiently transport electrons from one
complex to another. These results are very similar to those demonstrat-
ing enhanced ROS production by reactivation of the TCA cycle as a re-
sult of PDH activation by DCA [20].
It has been suggested that tumors from NSCLC patients with en-
hanced LDH-A expression are resistant to chemotherapy treatment
because of the highly acidic tumor microenvironment [8]. We wanted
to ask whether inhibition of LDH-A with low lactate production will
aid in enhancing the potential effect of the chemotherapy regimen. We
show that LDH-A inhibition results in decreased extracellular acidifica-
tion by traditional measurement of lactate content as well as by PPR
measurement using the XZ-24 analyzer and that low-dose paclitaxel
has an additive effect in enhancing apoptosis in LDH-A–deficient cells.
These results are in line with previous studies [58] that describe mark-
edly enhanced toxicity of paclitaxel and 2-deoxy-D-glucose in combina-
tion in NSCLC xenografts because LDH-A inhibition by directing the
trafficking of pyruvate to acetyl CoA is likely to also decrease glycolytic
flux as does 2-deoxy-D-glucose.
Many cancer drugs often exhibit toxicity in nonmalignant tissues,
partly because their targets are also expressed in these tissues. Inhibition
of LDH-A makes it an attractive target in cancer therapy because its
expression is largely relegated to the skeletal muscle. Moreover, humans
with LDH-A deficiency show a relatively normal phenotype and exhibit
myoglobinuria under intense anaerobic exercising. Moreover, LDH-A
inhibition may be better suited in combination with chemotherapeutic
regimen because most of the current therapies are inadequate to target
hypoxic region that may potentially harbor stem cells. Thus, the devel-
opment of inhibitors of LDH-Amakes eminent sense for the treatment
of a potentially large group of cancers in which the Warburg effect is
operational, perhaps as many as 60% to 80% of tumor types.
Our demonstration that inhibition of fermentative glycolysis by small
molecule inhibitor can be imaged noninvasively and in real time may
allow for a novel surrogate clinical end point: the capacity to monitor
the fate of pyruvate. Thus, dosing and scheduling of DCA administra-
tion can be optimized for maximal effects on changes in pyruvate flux
rather than being governed by toxicity end points. Such a capacity could
provide valuable first-in-human data for drugs that target the fate of
pyruvate and aim to reverse theWarburg effect: drugs that either inhibit
LDH-A or enhance the PDH complex. This capability can streamline
development of this drug class and potentially reduce costs by providing
early “go, no go” decisions that are mechanistically based. The proposed
technology—use of hyperpolarizedMRI—is scalable to human use and
has broad applicability in this regard because most solid tumors exhibit
the Warburg effect.
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